Effect of rise in simulated inspiratory flow rate and carrier particle size on powder emptying from dry powder inhalers

AAPS PharmSci

Volumn 2, Issue 2, 2000, Pages 1-7

  Chavan, Varsha ^a   Dalby, Richard ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 18044404862     PISSN: 15221059     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps020210     Document Type: Article

References (16)

1. Rees J, Price J. Asthma in children: treatment. BMJ. 1995; 310:1522-1527.
2. Cutie A, Sciarra J. Therapeutic inhalation aerosols in the treatment of asthma. Am J of Hosp Pharm. 1989;46:1845-1855.
3. Prime D, Atkins P, Slater A , Sumby B. Review of dry powder inhalers. Advanced Drug Delivery Reviews. 1997;26:51-58.
4. Bell J, Treneman B. Design and engineering of dry powder inhalers. Respiratory Drug Delivery IV. Buffalo Grove, IL: Interpharm Press; 1994:93-99.
5. Nantel N, Newhouse M. Inspiratory flow rates through a novel dry powder inhaler (Clickhaler) in pediatric patients with asthma. J Aerosol Med. 1999;12:55-58.
6. Lucas P, Andersen K, Staniforth J. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers. Pharm Res. 1998;15:562-568.
7. Hindle M, Byron P. Dose emissions from marketed dry powder inhalers. Int J Pharm. 1995;169-176.
8. Clark A, Bailey R. Inspiratory flow profiles in disease and their effects on the delivery characteristics of dry powder inhalers. Respiratory Drug Delivery IV. Buffalo Grove, IL: Interpharm Press; 1996:221-228.
9. Hickey J, Concessio N, Platz R. Factors influencing the dispersion of dry powders as aerosols. PharmTech. 1994;18:58-64.
10. Srichana T, Martin G, Marriott C. The relationship between drug and carrier deposition from dry powder inhalers in vitro. Int J Pharm. 1998;167:13-23.
11. DeBoer A, Winter H, Lerk C. Part 1. Inhalation characteristics, work of breathing and volunteer's preferences in dependence of the inhaler resistance. Int J Pharm. 1996;130:231-244.
12. DeBoer A, Gjaltema D, Hagedoorn P. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 2. Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int J Pharm. 1996;138:45-46.
13. Steckel H, Muller B. In vitro evaluation of Dry Powder Inhalers. Part 2. Influence of carrier particle size and concentration on in vitro deposition. Int J Pharm. 1997;154:31-37.
14. Byron P. Compendial dry powder testing: USP perspectives. Respiratory Drug Delivery IV. Buffalo Grove, IL: Interpharm Press; 1994:153-162.
15. Stimuli to the revision process. Pharmacopeial Forum 23. 1997;6:5216
16. Clark A, Hollingworth A. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers. Implications for in vitro testing. J Aerosol Med. 1993;6:99-110.